The U.S. FDA has rejected Verrica Pharmaceuticals Inc.’s drug-device combination to treat the viral skin disease molluscum for a third time, losing more ground to a...

Pleno Inc. has secured $15 million in a pre-series A financing led by Medical Excellence Capital and Alexandria Venture Investments. The proceeds will support development...

Jack Taunton and colleagues from the University of California, San Francisco have developed salicylaldehyde-based chemical probes that reversibly and covalently modify the catalytic lysine of protein kinases, with sustained occupancy in cells and animals.

Turning Point Therapeutics Inc. has picked up near-global rights to develop and commercialize an antibody drug conjugate (ADC) targeting Claudin18.2 from Lanova Medicines...